Connor, Clark & Lunn Investment Management (CC&L)
VIR icon

Connor, Clark & Lunn Investment Management (CC&L)’s Vir Biotechnology VIR Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-83,618
Closed -$3.5M – 1232
2021
Q4 		$3.5M Sell
83,618
-40,612
-33% -$1.59M 0.02% 404
2021
Q3 		$5.41M Buy
+124,230
New +$5.38M 0.03% 320

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.44B AUM 23.16% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s VIR Position: Q1 2022 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Vir Biotechnology (VIR) in Q1 2022, closing a stake of 83,618 shares — an estimated $3.5M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in VIR in Q3 2021 and held it in 2 quarters. The position peaked at $5.41M in Q3 2021. 204 funds tracked by Wall St. Rank hold VIR as of Q1 2022.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Vir Biotechnology position as of Q1 2022 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 83,618 Vir Biotechnology shares in Q1 2022, an estimated $3.5M.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Vir Biotechnology in Q3 2021 and held it in 2 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Vir Biotechnology position peaked at $5.41M in Q3 2021.
  • 204 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2022.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2022, filed 12 May 2022.